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Introduction: This phase I/IIA study evaluated the maximum-toler-
ated dose (MTD), safety, and clinical benefit of pomalidomide, an 
immunomodulatory drug (IMiD), combined with cisplatin+etoposide 
chemotherapy, in treatment-naive patients with extensive-stage (ES) 
small-cell lung cancer (SCLC).
Methods: In this multicenter, open-label, dose-escalation study, 
patients received 21-day cycles of oral pomalidomide (1, 3, 5, and 
4 mg/day) on days 1 to 14, plus cisplatin 25 mg/m2 and etoposide 
100 mg/m2 administered intravenously on days 1 to 3; the MTD was 
determined during cycle 1 (standard 3+3 dose-escalation design), 
followed by a five-cycle extension phase.
Results: Twenty-two patients with ES SCLC, with a median age 
of 64.5 years received one or more doses of the study medication. 
Dose-limiting toxicities included grade 4 cerebral ischemia and 
grade 5 sepsis (1-mg cohort), grade 4 transient ischemic attack 
(5-mg cohort), and grade 5 neutropenic infection (5-mg cohort). The 
MTD for pomalidomide was 4 mg/day. In the MTD phase, the most 
common pomalidomide-related adverse events (AEs) were fatigue 
(72.7%), nausea (45.5%), and neutropenia (40.9%); 31.8% of patients 
experienced pomalidomide-related serious AEs and 40.9% cisplatin/
etoposide-related serious AEs. Overall response rate was 31.8% 
(7 of 22); these were partial responses. Stable disease and progressive 
disease occurred in four patients (18.2%) each. The median response 
duration was 12.4 weeks. Median overall survival was 49.6 weeks.
Conclusions: Pomalidomide at the MTD of 4 mg/day plus standard 
cisplatin+etoposide seems safe in treatment-naive patients with ES 
SCLC. However, addition of pomalidomide does not seem to improve 
the therapeutic index of chemotherapy alone.
Key Words: Pomalidomide, Chemotherapy, Extensive-stage small-
cell lung cancer, Phase I trial, First-line therapy.
(J Thorac Oncol. 2013;8: 423-428)
Small-cell lung cancer (SCLC) represents approximately 15% of all lung cancers.1 SCLC is associated with rapid 
tumor doubling and early metastatic spread. SCLC is highly 
responsive to chemotherapy and radiotherapy; however, most 
patients relapse within 2 years of treatment and die from recur-
rent disease.1 There has been little improvement in survival for 
SCLC in recent decades, despite the evaluation of multiple 
new agents and approaches.2 The addition of biological and 
targeted agents has also been unsuccessful.3,4
An analysis of historical randomized studies in SCLC 
revealed a median survival of 7.0 months in studies performed 
from 1972 to 1981, whereas those performed from 1982 to 
1990 reported a median survival of 8.9 months (p = 0.001).2 
This modest improvement is likely because of the introduc-
tion of the cisplatin+etoposide regimen as a standard therapy 
in the early 1980s,2 and this outcome has remained consistent 
over the past two decades. Currently, median survival ranges 
between 9 and 11 months, with less than 5% of patients sur-
viving beyond 2 years.1
Immunomodulatory drugs (IMiDs) improve survival 
among patients with multiple myeloma, and combination 
regimens including IMiDs and chemotherapeutic agents 
have demonstrated efficacy in relapsed or refractory disease.5 
Pomalidomide (CC-4047; Celgene Corporation, Summit, NJ) 
is an immunomodulatory compound with potent antiangio-
genic and tumoricidal effects.6–10 Pomalidomide has been 
shown to inhibit proangiogenic factors, vascular endothelial 
growth factor, and basic fibroblast growth factor,7–9 which 
promote tumor cell proliferation and migration and are asso-
ciated with poor prognosis in lung cancer.11,12 Pomalidomide 
has demonstrated antitumor activity and tolerability in combi-
nation with gemcitabine in metastatic pancreatic cancer13 and 
has been evaluated in another study in patients with various 
solid tumors.14
The aim of this study was to determine the maximum-
tolerated dose (MTD) and safety profile of pomalidomide 
administered with cisplatin+etoposide in chemotherapy-naive 
patients with extensive-stage (ES) SCLC.
PATIENTS AND METHODS
Study Population
Chemotherapy-naive patients aged 18 years and older 
with histologically or cytologically confirmed ES SCLC were 
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eligible, if they had an Eastern Cooperative Oncology group 
performance status (ECOg PS) of 0, 1, or 2. Written informed 
consent was obtained from all the patients. The study was 
approved by each institution’s research Ethics Board. 
Screening for protocol eligibility was conducted within 4 
weeks of treatment initiation.
Study Design and Treatment Schedule
This was a multicenter, phase I, open-label, dose-escala-
tion study (www.ClinicalTrials.gov: NCT00537511) designed 
to determine the MTD of pomalidomide in combination with 
cisplatin+etoposide chemotherapy (Fig. 1).
Eligible patients were enrolled into cohorts of three 
patients. Chemotherapy consisted of intravenous (IV) cispla-
tin 25 mg/m2 and etoposide 100 mg/m2 on days 1 to 3 of each 
21-day cycle. Pomalidomide was administered orally at doses 
of 1, 3, or 5 mg/day on days 1 to 14. Dose escalation followed 
a standard phase I 3+3 design. If MTD was exceeded at 3- or 
5-mg pomalidomide, the next dose levels would be reduced 
by 1 mg; if MTD was exceeded at 1 mg, the next dose level 
would be 0.5 mg.
Adverse events (AEs) were graded in accordance with 
the National Cancer Institute Common Toxicity Criteria for 
AEs (NCI CTCAE) version 4.0. The MTD, determined dur-
ing cycle 1, was defined as the highest dose level at which no 
more than one of six patients experienced a dose-limiting tox-
icity (DLT). Six additional patients were assigned to receive 
pomalidomide at the MTD with cisplatin+etoposide. Patients 
experiencing a DLT during cycle 1 were allowed to continue 
on study, at the investigator’s discretion. Patients without DLT 
or progressive disease at the end of cycle 1 could receive up 
to six treatment cycles (extension period). Patients without 
disease progression after six cycles of pomalidomide plus 
cisplatin+etoposide could continue with pomalidomide alone. 
Three weeks after the last chemotherapy, the pomalidomide 
dose was increased to 5 mg daily (days 1–14 of each 21-day 
cycle) for this maintenance period.
response was assessed every three cycles, using 
response Evaluation Criteria in Solid Tumors.15 For patients 
continuing pomalidomide after chemotherapy, response was 
assessed every three cycles.
Hematopoietic growth factors as prophylaxis or man-
aging of hematologic toxicities were not allowed in cycle 1. 
However, subsequent use of hematopoietic growth factors was 
allowed.
Study Endpoints
The primary objective was to identify the MTD of 
pomalidomide administered with cisplatin+etoposide in 
patients with ES SCLC. Secondary objectives included safety, 
investigator-determined overall response rate (Orr), response 
duration, and overall survival (OS).
Statistical Analysis
A 3+3 design was used to determine the MTD during 
cycle 1 and was defined as the highest dose level at which no 
more than one of six patients experienced a DLT. response, 
on the basis of response Evaluation Criteria in Solid Tumors 
version 1.0, was assessed by the investigators and was summa-
rized by treatment cohort for the intent-to-treat population.15
RESULTS
Baseline Characteristics and Treatment
Twenty-two patients with ES SCLC were enrolled; 
median age was 64.5 years (range, 49–77 years), 81.8% were 
men, and 27.3% had an ECOg PS of 2 (Table 1).
Four dosing cohorts of pomalidomide were evaluated: 
1 mg/day (6 patients), 3 mg/day (4 patients), as well as 5 mg/
day and 4 mg/day (6 patients each). All patients received at 
least one pomalidomide dose. Four patients discontinued 
because of AEs, two died, and one received growth factors 
for neutropenia during cycle 1 and was therefore withdrawn 
FIGURE 1.   Patient disposition and trial profile. A, Start of 
21-day cycle of treatment: cisplatin+etoposide administered 
intravenously on days 1 to 3 of each cycle; pomalidomide 
administered orally for 14 consecutive days beginning on 
day 1. DLT, dose-limiting toxicity; MTD, maximum-tolerated 
dose; PD, progressive disease.
TABLE 1.  Baseline Characteristics
Characteristic N = 22
Age
 Median, yr (range) 64.5 (49–77)
 ≤65 yr, n (%) 12 (54.5)
 ≥65 yr, n (%) 10 (45.5)
 Male, n (%) 18 (81.8)
ECOg PS score, n (%)
 0 2 (9.1)
 1 14 (63.6)
 2 6 (27.3)
ECOg PS, Eastern Cooperative Oncology group performance status.
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in accordance with the eligibility criteria. One patient was not 
evaluated while on treatment for unknown reasons.
Dose-Limiting Toxicity
DLTs per dose are summarized in Table 2. At the 
pomalidomide 5-mg dose level, two DLTs were observed 
(transient ischemic attack/cerebrovascular accident and 
neutropenic infection); therefore, pomalidomide was 
de-escalated to 4 mg daily. The median treatment duration 
with pomalidomide for all patients was 20.5 weeks; median 
durations were longer in the 1- and 3-mg cohorts than in the 
4- and 5-mg cohorts (17.9 and 17.0 weeks versus 14.0 and 
13.0 weeks, respectively). Nine patients did not receive all the 
six treatment cycles during phase I of the study (5 patients 
received 1 cycle, 1 received 2 cycles, and 3 received 4 cycles). 
reasons for discontinuation were AEs, death, withdrawal 
of consent, progression of disease, and others. Overall, 
four DLTs were observed among three patients for which a 
relationship with pomalidomide and cisplatin+etoposide was 
suspected. One patient in the 1-mg pomalidomide cohort had 
grade 4 cerebral ischemia and grade 3 convulsions and died of 
sepsis. In the 5-mg cohort, one patient had a grade 4 transient 
ischemic attack and another experienced fatal neutropenic 
infection. In both patients, treatment with pomalidomide and 
cisplatin+etoposide had been withdrawn.
The MTD of pomalidomide was established as 4 mg on 
days 1 to 14 with cisplatin+etoposide. In this cohort, three 
patients (50%) required a dose delay of cisplatin (n = 2), 
etoposide (n = 1), and/or pomalidomide (n = 3); none of the 
patients required a dose reduction. Patients in the 5-mg cohort 
received fewer cycles of chemotherapy, suggesting that the 
addition of pomalidomide at this dose level compromised the 
ability to deliver standard doses of chemotherapy.
Safety
All 22 patients were included in the safety analysis, and 
all discontinued the study treatment: five during cycle 1, six 
during cycles 2 to 6, three during or at the end of cycle 7, 
and eight during the pomalidomide maintenance period. Most 
patients (13 of 22; 59.1%) discontinued the study treatment 
because of disease progression and four patients (18.2%) 
because of AEs; two patients (9.1%) died because of sepsis 
and pulmonary emboli.
Most AEs were grade 1 or 2; however, all patients expe-
rienced at least one AE of grade 3 or higher. The most common 
AEs of all grades were fatigue (95.5%), nausea (68.2%), con-
stipation (54.5%), neutropenia (54.5%), anemia (40.9%), 
alopecia (54.5%), and rash (27.3%). grade 1 to 2 renal dys-
function was observed in three patients. With the exception 
of nausea, constipation, and neutropenia, which occurred 
more frequently in the 4- and 5-mg cohorts, a relationship 
between the frequency of AEs and pomalidomide dose level 
was not suspected. The most common AEs (all grades) related 
to pomalidomide were fatigue (72.7%), nausea (45.5%), and 
neutropenia (40.9%).
Pomalidomide-related serious AEs were observed in 
31.8% of patients, and 40.9% of patients experienced cis-
platin- and/or etoposide-related serious AEs. Serious AEs of 
neutropenic infection, febrile neutropenia, cerebral ischemia, 
pulmonary embolism, sepsis, fatigue, convulsion, diverticular 
perforation, and increased blood creatinine were in most cases 
suspected to be related to the study treatment (pomalidomide 
and/or cisplatin+etoposide). Sixteen patients died during the 
study: most deaths (13 of 16; 81%) resulted from underlying 
disease and occurred more than 30 days after treatment dis-
continuation. Three subjects died of causes other than disease 
progression: central nervous system cerebrovascular ischemia 
(suspected to be related to both pomalidomide and cisplatin 
and/or etoposide), pulmonary emboli (suspected to be related 
to cisplatin and/or etoposide), and unknown cause (125 days 
after the last dose of pomalidomide).
The most common grade 3 or higher AEs were 
neutropenia (55%), thrombocytopenia (9%), and anemia 
(23%) (Table 3). Neutropenia of grade 3 and higher was 
seen more frequently with higher pomalidomide dose levels: 
83.3% of patients in the 5-mg pomalidomide cohort versus 
33.3% in the 1-mg cohort, and 50% in each of the 3- and 4-mg 
cohorts. The most common grade 3 to 4 nonhematologic AE 
was fatigue (18.2%). Other grade 3 to 4 AEs that occurred in 
at least two patients included anemia and cerebral ischemia. 
grade 4 AEs were less frequent in the 1- and 3-mg cohorts 
compared with those in the 4- and 5-mg cohorts. grade 5 AEs 
were observed in three patients and included sepsis (1-mg 
cohort), pulmonary embolism (4-mg cohort), and neutropenic 
infection (5-mg cohort).
Response
Investigator-assessed Orr was 31.8%, with all responses 
(7 of 22 patients) being partial responses (Prs) (Table 4). 
Four patients (18.2%) had unconfirmed Pr, listed in Table 4 
as stable disease. Four patients (18.2%) had progressive dis-
ease. Of the remaining patients, six discontinued before the 
first postbaseline assessment and one was not evaluated for 
reasons unknown. There was no evidence of a dose–response 
effect for pomalidomide.
The median response duration for responding patients 
was 12.4 weeks (range, 0.1–19.4) (Table 4). There was one 
unconfirmed Pr in the 5-mg group that lasted less than 4 
weeks as the patient was hospitalized for diverticular perfora-
tion after cycle 4 and died from SCLC. In the remaining 10 
responders, response duration varied from 4 to 19.4 weeks. 
At the time of study closure, four patients (18%) were cen-
sored for response duration because either their disease had 
TABLE 2.  Dose-Limiting Toxicities (N = 22)
Pomalidomide,  
mg
Patients, 
n (%)
DLTs,  
n (%) DLT
1 6 (27.3) 1 (16.7) Cerebral ischemia, sepsis
3 4 (18.2) 0 NA
4 6 (27.3) 0 NA
5 6 (27.3) 2 (33.3) TIA/CVA and neutropenic infection
CVA, cerebrovascular accident; DLT, dose-limiting toxicity; NA, not applicable; 
TIA, transient ischemic attack.
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not progressed or they had discontinued the treatment before 
progression was documented.
At the time of study closure, six patients (27%) were 
alive and were therefore censored for the OS analysis. The 
median OS was 49.6 weeks (95% confidence interval: 
28.0–63.9).
As the observed Orr for pomalidomide and 
cisplatin+etoposide in this study was consistent with pub-
lished data for cisplatin+etoposide alone, and the secondary 
endpoint for median OS had been reached, the study was ter-
minated and phase II investigation canceled.
DISCUSSION
This phase I study demonstrated that the MTD of 
pomalidomide was 4 mg on days 1 to 14 in combination with 
IV cisplatin 25 mg/m2 and IV etoposide 100 mg/m2. Patients 
discontinued treatment primarily (59.1%) because of dis-
ease progression. The most common AE leading to treat-
ment modification was grade 3 to 4 neutropenia, which in 
the majority of cases, was suspected to be related to both 
pomalidomide and cisplatin+etoposide. Neutropenia led to 
transient treatment interruption but not treatment discontin-
uation; furthermore, no change to the dose of pomalidomide 
or cisplatin+etoposide occurred after treatment interruption. 
This neutropenia rate is comparable with those reported in 
previous studies investigating cisplatin+etoposide in exten-
sive disease SCLC.16–18 Neutropenia of grade 3 or higher 
seemed to be more frequent in the 5-mg cohort (83.3% ver-
sus 33.3% in the 1-mg cohort and with 50% in the 3- and 
4-mg cohorts).
The AE profile of pomalidomide combined with 
cisplatin+etoposide was consistent with that observed 
in patients with ES SCLC who were treated with 
cisplatin+etoposide alone; notably, pomalidomide was not 
associated with any serious (grade ≥3), treatment-related 
renal toxicities.16–18 The AE profile for pomalidomide in 
this study was also consistent with that observed in trials 
of pomalidomide in multiple myeloma.19,20 Fatigue was 
one of the most common nonhematologic AEs of grade 3 
or 4. Fourteen patients (63.6%) experienced at least one 
treatment-emergent AE (TEAE) that led to dose reduction or 
interruption of pomalidomide and 13 (59.1%) experienced 
one or more TEAEs that led to dose reduction or interruption 
of cisplatin and/or etoposide. However, patients in the 5-mg 
cohort seemed to receive fewer cycles of chemotherapy 
than patients in the 1- or 3-mg cohorts (median number 
of cycles 4 versus 6). This highlights the need for dose-
escalation schedules to consider not only the toxicity 
experienced during cycle 1, but also the impact of toxicity 
in subsequent cycles of treatment. There was no relationship 
between chemotherapy dose reduction or interruption and 
pomalidomide dose.
The Orr for pomalidomide in combination with 
cisplatin+etoposide was consistent with published data 
for cisplatin+etoposide given alone.18,21,22 The addition of 
pomalidomide to cisplatin+etoposide did not seem to improve 
the Orr (32%) or survival compared with published data for 
cisplatin+etoposide alone.18,21,22 These results are disappointing 
because previous trials with thalidomide suggested a possible 
benefit for this agent. In one trial, 119 patients with ES 
SCLC, who had responded to two cycles of etoposide, 
cisplatin, cyclophosphamide, and 4′-epidoxorubicin (PCDE) 
received thalidomide 400 mg/day or placebo with their four 
subsequent chemotherapy cycles.23 Progression-free survival 
(PFS) and OS were longer in the thalidomide arm, although 
the differences were not significant (OS, p = 0.16; PFS, p = 
0.015); however, the difference was significant in patients with 
an ECOg PS score of 1 or 2 (OS, p = 0.02; PFS, p = 0.02). 
Patients receiving thalidomide had an increased incidence of 
sensory neuropathy of grade 2 or higher. In another study, 
TABLE 3.   Treatment-Emergent Adverse Events Grade ≥3 Occurring in ≥2 Patients (Safety Population)
AE Preferred Term, n (%)
Pomalidomide Dose cohorts
1 mg (n = 6) 3 mg (n = 4) 4 mg (n = 6) 5 mg (n = 6) Overall (N = 22)
≥1 AE, grade ≥3 6 (100) 4 (100) 6 (100) 6 (100) 22 (100)
Hematologic
 Anemia 1 (16.7) 2 (50.0) 2 (33.3) 0 5 (22.7)
 Thrombocytopenia 0 0 0 2 (33.3) 2 (9.1)
 Neutropenia 2 (33.3) 2 (50.0) 3 (50.0) 5 (83.3) 12 (54.5)
 Febrile neutropenia 0 1 (25.0) 0 1 (16.7) 2 (9.1)
Nonhematologic
 Fatigue 3 (50.0) 0 0 1 (16.7) 4 (18.2)
 Muscular weakness 1 (16.7) 1 (25.0) 0 0 2 (9.1)
 Cerebral ischemia 1 (16.7) 0 0 1 (16.7) 2 (9.1)
 Convulsion 1 (16.7) 0 1 (16.7) 0 2 (9.1)
 Dyspnea 1 (16.7) 0 1 (16.7) 0 2 (9.1)
 Hypotension 0 0 1 (16.7) 1 (16.7) 2 (9.1)
 Pulmonary embolism 0 0 1 (16.7) 0 1 (4.5)
AE, adverse event.
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thalidomide 100 to 200 mg/day or placebo was combined with 
etoposide+carboplatin in patients with both limited-stage or 
ES SCLC.24 There was no difference in OS (10.1 versus 10.5 
months) in the total patient population; furthermore, in ES 
patients, thalidomide was associated with worse OS compared 
with placebo (8.0 versus 9.1 months; p = 0.011). Thalidomide 
also led to a higher incidence of thrombotic events compared 
with placebo (19 versus 10%; p < 0.001).
In conclusion, although pomalidomide may be com-
bined with cisplatin+etoposide chemotherapy for ES 
SCLC, it does not seem to improve the therapeutic index of 
cisplatin+etoposide alone. On the basis of these data, pomalid-
omide does not warrant further study in ES SCLC.
ACKNOWLEDGMENTS
This study was funded by Celgene Corporation. Medical 
writing services were provided by Marlene Knippenberg, 
PhD, Ronald van Olffen, PhD, and Kim Grootscholten, MSc, 
of Excerpta Medica.
REFERENCES
 1. National Comprehensive Cancer Network. Clinical practice guidelines 
in oncology: small cell lung cancer. Version 2, 2012 [NCCN web site]. 
Available at: www.nccn.org. Accessed 15 June 2012.
 2. Chute JP, Chen T, Feigal E, Simon r, Johnson BE. Twenty years of phase 
III trials for patients with extensive-stage small-cell lung cancer: percep-
tible progress. J Clin Oncol 1999;17:1794–1801.
 3. Dowell JE. Small-cell lung cancer: are we making progress? Am J Med 
Sci 2010;339:68–76.
 4. Abidin AZ, garassino MC, Califano r, Harle A, Blackhall F. Targeted 
therapies in small cell lung cancer: a review. Ther Adv Med Oncol 
2010;2:25–37.
 5. Stewart AK. Novel therapies for relapsed myeloma. Hematology Am Soc 
Hematol Educ Program 2009;1:578–586.
 6. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs 
overcome drug resistance of human multiple myeloma cells to conven-
tional therapy. Blood 2000;96:2943–2950.
 7. Dredge K, Marriott JB, Macdonald CD, et al. Novel thalidomide ana-
logues display anti-angiogenic activity independently of immunomodula-
tory effects. Br J Cancer 2002;87:1166–1172.
 8. Lentzsch S, rogers MS, LeBlanc r, et al. S-3-Amino-phthalimido-
glutarimide inhibits angiogenesis and growth of B-cell neoplasias in 
mice. Cancer Res 2002;62:2300–2305.
 9. Bartlett JB, Dredge K, Dalgleish Ag. The evolution of thalido-
mide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 
2004;4:314–322.
 10. Zhu D, Corral Lg, Fleming YW, Stein B. Immunomodulatory drugs 
revlimid (lenalidomide) and CC-4047 induce apoptosis of both hemato-
logical and solid tumor cells through NK cell activation. Cancer Immunol 
Immunother 2008;57:1849–1859.
 11. Tanno S, Ohsaki Y, Nakanishi K, Toyoshima E, Kikuchi K. Human small 
cell lung cancer cells express functional VEgF receptors, VEgFr-2 and 
VEgFr-3. Lung Cancer 2004;46:11–19.
 12. ruotsalainen T, Joensuu H, Mattson K, Salven P. High pretreatment 
serum concentration of basic fibroblast growth factor is a predictor of 
poor prognosis in small cell lung cancer. Cancer Epidemiol Biomarkers 
Prev 2002;11:1492–1495.
 13. Infante Jr, Jones SF, Bendell JC, et al. A phase I, dose-escalation study of 
pomalidomide (CC-4047) in combination with gemcitabine in metastatic 
pancreas cancer. Eur J Cancer 2011;47:199–205.
 14. Cooney MM, Bokar JA, Dreicer r, et al. Phase I trial of daily pomalido-
mide in patients with advanced solid tumors. J Clin Oncol 2010;28(Supp
l):Abstract e13077.
 15. Therasse P, Arbuck Sg, Eisenhauer EA, et al. New guidelines to evalu-
ate the response to treatment in solid tumors. European Organization 
for research and Treatment of Cancer, National Cancer Institute of the 
United States, National Cancer Institute of Canada. J Natl Cancer Inst 
2000;92:205–216.
 16. Hanna N, Bunn PA Jr, Langer C, et al. randomized phase III trial com-
paring irinotecan/cisplatin with etoposide/cisplatin in patients with pre-
viously untreated extensive-stage disease small-cell lung cancer. J Clin 
Oncol 2006;24:2038–2043.
 17. Lara PN Jr, Natale r, Crowley J, et al. Phase III trial of irinotecan/cispla-
tin compared with etoposide/cisplatin in extensive-stage small-cell lung 
cancer: clinical and pharmacogenomic results from SWOg S0124. J Clin 
Oncol 2009;27:2530–2535.
 18. Heigener DF, Freitag L, Eschbach C, et al. Topetecan/cisplatin (TP) com-
pared to cisplatin/etoposide (PE) for patients with extensive disease-small 
cell lung cancer (ED-SCLC): final results of a randomised phase III trial. 
J Clin Oncol 2008;26(Suppl):Abstract 7513.
 19. Lacy MQ, Hayman Sr, gertz MA, et al. Pomalidomide (CC4047) plus 
low-dose dexamethasone as therapy for relapsed multiple myeloma. J 
Clin Oncol 2009;27:5008–5014.
 20. Lacy MQ, Allred JB, gertz MA, et al. Pomalidomide plus low-dose 
dexamethasone in myeloma refractory to both bortezomib and lenalido-
mide: comparison of 2 dosing strategies in dual-refractory disease. Blood 
2011;118:2970–2975.
TABLE 4.   Summary of Clinical Efficacy Assessment (Intent-to-Treat Population)
Response
Pomalidomide dose cohorts
1 mg (n = 6) 3 mg (n = 4) 4 mg (n = 6) 5 mg (n = 6) Overall (N = 22)
Orr (Cr + Pr), n (%) 1 (16.7) 2 (50.0) 2 (33.3) 2 (33.3) 7 (31.8)
 Cr, n (%) 0 0 0 0 0
 Pr, n (%) 1 (16.7) 2 (50.0) 2 (33.3) 2 (33.3) 7 (31.8)
SD (unconfirmed Pr), n (%) 2 (33.3) 1 (25.0) 0 1 (16.7) 4 (18.2)a
PD, n (%) 1 (16.7) 1 (25.0) 1 (16.7) 1 (16.7) 4 (18.2)
Not evaluated, n (%) 0 0 1 (16.7) 0 1 (4.5)
Discontinuedb, n (%) 2 (33.3) 0 2 (33.3) 2 (33.3) 6 (27.3)
Median response duration, weeks (range) 12.4 (0.1–19.4)
Median OS, weeks (95% CI) 49.6 (28.0–63.9)
aOne patient demonstrated unconfirmed Pr that lasted less than 4 weeks and died from SCLC; three patients demonstrated unconfirmed PD after one report of Pr.
bPatients discontinued before first postbaseline assessment.
CI, confidence interval; Cr, complete response; Orr, overall response rate; OS, overall survival; PD, progressive disease; Pr, partial response.
428 Copyright © 2013 by the International Association for the Study of Lung Cancer
Ellis et al. Journal of Thoracic Oncology  •  Volume 8, Number 4, April 2013
 21. Lee SM, James LE, Qian W, et al. Comparison of gemcitabine and car-
boplatin versus cisplatin and etoposide for patients with poor-prognosis 
small cell lung cancer. Thorax 2009;64:75–80.
 22. O’Brien ME, Konopa K, Lorigan P, et al. randomised phase II study 
of amrubicin as single agent or in combination with cisplatin ver-
sus cisplatin etoposide as first-line treatment in patients with exten-
sive stage small cell lung cancer – EOrTC 08062. Eur J Cancer 
2011;47:2322–2330.
 23. Pujol JL, Breton JL, gervais r, et al. Phase III double-blind, placebo-
controlled study of thalidomide in extensive-disease small-cell lung can-
cer after response to chemotherapy: an intergroup study FNCLCC cleo04 
IFCT 00-01. J Clin Oncol 2007;25:3945–3951.
 24. Lee SM, Woll PJ, rudd r, et al. Anti-angiogenic therapy using tha-
lidomide combined with chemotherapy in small cell lung cancer: a 
randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 
2009;101:1049–1057.
